To determine if there was any difference in the ability of physicians to predict prognosis with technetium 99m ((99m)Tc) sestamibi or (99m)Tc tetrofosmin in a large consecutive series of patients at high risk for coronary artery disease who underwent coronary angiography.
Department of Medicine, Duke Clinical Research Institute and Drexel School of Medicine, Duke University Medical Center, PO Box 3949, Durham, NC 27710, USA. borge001@mc.duke.edu